MSD at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
MSD takes part in 6 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8030. Its program spans ovarian and endometrial cancer, kidney and muscle-invasive bladder cancer, resectable head and neck cancer and extensive-stage small cell lung cancer. It also covers diagnostic barriers to precision medicine and nursing care for immunotherapy given under the skin.
| Organization | ESMO 2026 Attendance |
|---|---|
Global pharmaceutical company, known as Merck & Co. in the US and Canada, whose oncology medicines include pembrolizumab. | Booth Exhibiting at Booth 8030 Satellite Fri Oct 23 09:45–11:15 MSD - Emerging Evidence and Treatment Integration in Ovarian and Endometrial Cancer Gynaecological cancersBiomarkers & precision oncology Satellite Sat Oct 24 12:00–13:30 Satellite Sat Oct 24 13:00–14:30 MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC Sarcoma, CNS, head & neck and rare cancers Satellite Sun Oct 25 18:30–20:00 MSD - Is the precision medicine ecosystem ready? Overcoming diagnostic barriers in oncology Biomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers Satellite Mon Oct 26 13:00–14:30 |
Instantly find 20 buyers from MSD
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction